NCT05426486 2024-10-30A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsShengjing HospitalPhase 2/3 Active not recruiting136 enrolled
NCT05189067 2022-01-12Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast CancerSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2/3 Unknown190 enrolled